VEGFA and renal cell carcinoma: Several tyrosine-kinase inhibitors (TKIs) or monoclonal antibodies (bevacizumab, sunitinib and sorafenib) that block VEGFA mediated tyrosine-kinase pathways have been used to treat advanced RCC [10,58,59].